• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

PACS vendors shouldn't oversell the technology

Article

PACS vendors shouldn't oversell the technologyThe Radiological Society of North America meeting should be another superb event for vendors and prospective purchasers of PACS technology. With what appears to be another mediocre year for big-iron

PACS vendors shouldn't oversell the technology

The Radiological Society of North America meeting should be another superb event for vendors and prospective purchasers of PACS technology. With what appears to be another mediocre year for big-iron modality introductions, PACS is expected to garner the most attention on the exhibit floor for a third straight year.

Despite all that's going well for the PACS industry, however, there remains a tendency among some vendors to exaggerate the capabilities of their products. This mindset is an unfortunate carryover from the early days of PACS, when technology claims often far exceeded their capabilities. The over-hyping of digital image management left behind a wake of disillusioned early adopters, setting back wide-scale PACS adoption by several years.

Since then, however, PACS equipment has evolved at an exponential rate. Numerous successful implementations of large-scale PACS exist and there is widespread market acceptance of the benefits of digital image management. Problem areas do remain, though, particularly in the overplaying of abilities to integrate PACS with HIS/RIS networks, as well as conformance to DICOM and HL-7 standards. It can also be difficult to ascertain how many clients PACS vendors have, with several firms distorting the number of their "sites."

With PACS equipment still at a very low level of market penetration, nothing damages the technology's credibility more than another customer who's had to return a big-ticket purchase because it didn't perform as advertised. PACS companies must avoid overselling their capabilities to their customers. It will only hurt the industry in the long run.

-Erik L. Ridley, Editor

Recent Videos
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 2
Related Content
© 2025 MJH Life Sciences

All rights reserved.